Guus A M S van Dongen
Overview
Explore the profile of Guus A M S van Dongen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
129
Citations
4496
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wuensche T, Pereira P, Windhorst A, Bjerregaard-Andersen K, Sotty F, Kallunki P, et al.
Nucl Med Biol
. 2024 Nov;
140-141:108969.
PMID: 39591759
Background: Recently, Zr-immuno-PET imaging of therapeutic antibodies, actively transported over the blood-brain-barrier via transferrin-mediated transcytosis, was demonstrated using the chelator DFO*. In these studies, aducanumab targeting amyloid-beta was fused with...
2.
Wuensche T, Stergiou N, Mes I, Verlaan M, Kooijman E, Windhorst A, et al.
Mol Imaging Biol
. 2024 Aug;
26(5):823-834.
PMID: 39093482
Purpose: In the emerging field of antibody treatments for neurodegenerative diseases, reliable tools are needed to evaluate new therapeutics, diagnose and select patients, monitor disease progression, and assess therapy response....
3.
Muns J, Schooten E, van Dasselaar R, Noordman Y, Adamzek K, Eibergen A, et al.
Eur J Nucl Med Mol Imaging
. 2024 Jun;
51(12):3545-3558.
PMID: 38888612
Purpose: Hepatic fibrosis develops as a response to chronic liver injury, resulting in the formation of fibrous scars. This process is initiated and driven by collagen-producing activated myofibroblasts which reportedly...
4.
Wuensche T, Nauta S, van Dongen G, Vugts D
J Labelled Comp Radiopharm
. 2024 May;
67(8):280-287.
PMID: 38744538
A key aspect for the applicability of Zr-radioimmunoconjugates is inert modification and radiolabeling. The two commercially available bifunctional variants of the siderophore desferrioxamine (DFO), Fe-DFO-N-suc-TFP-ester and p-NCS-Bz-DFO, are most often...
5.
Wuensche T, Lyashchenko S, van Dongen G, Vugts D
EJNMMI Radiopharm Chem
. 2024 May;
9(1):40.
PMID: 38733556
Background: During the previous two decades, PET imaging of biopharmaceuticals radiolabeled with zirconium-89 has become a consistent tool in preclinical and clinical drug development and patient selection, primarily due to...
6.
Hognasbacka A, Poot A, Plisson C, Bergare J, Bonsall D, McCluskey S, et al.
EJNMMI Res
. 2024 Feb;
14(1):19.
PMID: 38363422
Background: Mutations in the epidermal growth factor receptor (EGFR) kinase domain are common in non-small cell lung cancer. Conventional tyrosine kinase inhibitors target the mutation site in the ATP binding...
7.
Wijngaarden J, Jauw Y, Zwezerijnen G, de Wit-van der Veen B, Vugts D, Zijlstra J, et al.
EJNMMI Res
. 2024 Feb;
14(1):18.
PMID: 38358425
Background: Distribution of mAbs into tumour tissue may occur via different processes contributing differently to the Zr-mAb uptake on PET. Target-specific binding in tumours is of main interest; however, non-specific...
8.
Wijngaarden J, Ahbari A, Pouw J, Greuter H, Bahce I, Zwezerijnen G, et al.
EJNMMI Phys
. 2024 Feb;
11(1):16.
PMID: 38321232
Background: PET scans using zirconium-89 labelled monoclonal antibodies (Zr-mAbs), known as Zr-immuno-PET, are made to measure uptake in tumour and organ tissue. Uptake is related to the supply of Zr-mAbs...
9.
Hognasbacka A, Poot A, Kooijman E, Schuit R, Schreurs M, Verlaan M, et al.
J Med Chem
. 2023 Aug;
66(17):12130-12140.
PMID: 37647220
Brigatinib, a tyrosine kinase inhibitor (TKI) with specificity for gene rearranged anaplastic lymphoma kinase (ALK), such as the EML4-ALK, has shown a potential to inhibit mutated epidermal growth factor receptor...
10.
Hognasbacka A, Poot A, Kooijman E, Schuit R, Schreurs M, Verlaan M, et al.
Nucl Med Biol
. 2023 May;
120-121:108349.
PMID: 37209556
Introduction: Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) that is able to inhibit the EGFR treatment resistance mutation T790M and primary EGFR mutations Del19 and L858R. The aim of...